<DOC>
	<DOCNO>NCT00923182</DOCNO>
	<brief_summary>The primary objective study confirm safety profile alemtuzumab 30 mg ( US/European Union ( EU ) approve dose ) Japanese patient relapse refractory Chronic Lymphocytic Leukemia ( CLL ) .</brief_summary>
	<brief_title>A Safety Confirmatory Study Alemtuzumab Japanese Patients With Relapsed Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>NOTE : This study previously post Bayer . In December 2009 , study acquire Genzyme Corporation . Genzyme Japan K.K . sponsor trial .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Bcell Chronic Lymphocytic Leukemia ( BCLL ) accord 1996 National Cancer Institutesponsored Working Group ( NCIWG ) Criteria One , &lt; = 3 previous treatment regimens Chronic Lymphocytic Leukemia ( CLL ) Patient require treatment CLL ( Rai stage III IV disease stage 0 II disease evidence progression ) Adequate bone marrow , liver renal function More 4 week since prior chemotherapy chemoimmunotherapy , include investigational agent , treatment CLL . Patient must recover acute side effect incur result previous therapy World Health Organization ( WHO ) Performance Status ( PS ) 0,1 Life expectancy least 24 week Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial 2 week completion trial Written inform consent Known human immunodeficiency virus ( HIV ) seropositivity Active hepatitis history prior viral hepatitis B hepatitis C , positive hepatitis B serology . Patients positive hepatitis B surface antibody ( HBsAb ) test document history prior hepatitis B immunization eligible long criterion meet ( i.e. , negative test : hepatitis B surface antigen [ HBsAg ] , hepatitis B core antibody [ HBcAb ] hepatitis C virus antibody [ HCVAb ] ) Active uncontrolled infection Recent document history ( within 2 year ) active tuberculosis ( TB ) , current active TB infection , currently receive antituberculous medication ( e.g. , isoniazid , rifampin , streptomycin , pyrazinamide , others ) Positive cytomegalovirus ( CMV ) Polymerase Chain Reaction ( PCR ) assay Transformation aggressive lymphoma ( e.g. , Richter 's syndrome ) Past history anaphylaxis follow exposure humanize monoclonal antibody Previous treatment alemtuzumab Previous hematopoietic stem cell transplant Pregnant breastfeeding patient Central nervous system ( CNS ) involvement CLL Other severe , concurrent disease ( e.g. , cardiac pulmonary disease ) , mental disorder , major organ malfunction ( e.g. , liver , kidney ) could interfere patient 's ability participate study Medical condition require chronic use oral corticosteroid dose high physiologic replacement . Active malignancy , CLL , need therapy anticancer drug ( ) Autoimmune anemia and/or thrombocytopenia Small lymphocytic lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Relapsed Refractory Chronic Lymphocytic Leukemia ,</keyword>
	<keyword>CLL</keyword>
</DOC>